Upcoming events
Previous presentations
Presentation from Annual General Meeting on May 11, 2023
Year-end report 2022
Interview with CEO Carl-Johan Dalsgaard with more details on the IPF program.
Vicore AIR interim 2 analysis, November 4, 2022
Presentation of the results from the second interim analysis of the phase 2a trial in IPF (AIR).
CEO presentation for the AGM 2022
Carl-Johan Dalsgaard presents important events during 2021 and the period thereafter.
R&D day, March 2022
The program included recent scientific progress, new indications being evaluated as well as an update on ongoing clinical trials. External presenters: Prof. Toby Maher, Prof. Maureen Horton and Dr Gerry Coghlan.
Webcast, February 10, 2022
Presentation of interim results from phase 2 trial in IPF
KOL webinar on C21 for the treatment of IPF
Hosting the medical doctors and IPF experts Prof. Toby Maher and Prof. Joanna Porter.
Redeye Life Science Days, November 11
Presentation of the investment case and QandA with CEO Carl-Johan Dalsgaard.
Redeye Growth Day, June 3 2021
CFO, Hans Jeppsson presented Vicore Pharma at Redeye Growth Day on June 3, 2021.
Corporate presentation, May 11 2021
CEO, Carl-Johan Dalsgaard gives an update on Vicore's operations for the virtual AGM.
DTx webinar, May 4 2021
Presentation on the digital therapeutic (DTx) program.
KOL webinar on COVID-19, April 28 2021
Presentation by KOL Professor Maureen Horton, M.D., Johns Hopkins University School of Medicine on the current treatment landscape and unmet medical needs in treating patients with COVID-19. Update on the results from Vicore's phase II study in COVID-19 and the coming phase III pivotal study.
Redeye interview, March 30 2021
Interview with CEO Carl-Johan Dalsgaard on the results from the phase II mechanistic study in systemic sclerosis (in Swedish).
Pareto interview, March 22 2021
Interview with CEO, Carl-Johan Dalsgaard on the results from the phase II mechanistic study in systemic sclerosis and the coming phase III study in COVID-19
Webcast presentation, Dec 21 2020
Presentation of expanded results from the phase II trial in COVID-19.
Redeye interview, Dec 11 2020
Interview with Carl-Johan Dalsgaard on COVID-19 top line data.
Webcast presentation, Dec 8 2020
Presentation of top line data from the phase II trial in COVID-19.
Stora aktiedagen, Nov 10 2020
CFO, Hans Jeppsson presented Vicore Pharma at Stora Aktiedagen in Gothenburg.
Pareto Securities Healthcare Conference, Sep 5 2020
Interview with CEO, Carl-Johan Dalsgaard during Pareto Securities Healthcare Conference.
Webcast presentations, Jun 3 2020
CEO, Carl-Johan Dalsgaard presented Vicore Pharma at Avanza digitala börsdag.
Webcast presentation, Apr 28 2020
CEO, Carl-Johan Dalsgaard presented the approved upcoming phase II study with VP01 in COVID-19.
Webcast presentation, Mar 31 2020
CEO, Carl-Johan Dalsgaard presented the planned phase II study with C21 in COVID-19.
Sitdown interview with Finwire, Dec 16 2019
Interview with CEO, Carl-Johan Dalsgaard (swedish only)